Spotlight
Video

Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of Phase 3 AXIS trial. ASCO 2011

videoblog has 63 videos Subscribe Here

Loading........
Description: Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of Phase 3 AXIS trial. ASCO 2011 (American Society of Clinical Oncology)
Shared By : videoblog
Posted on : 06/05/11
Added : 6 years ago
Category : General



More From videoblog

Nothing found.